Sax Wealth Advisors LLC Has $548,000 Stake in Zoetis Inc. $ZTS

Sax Wealth Advisors LLC trimmed its position in shares of Zoetis Inc. (NYSE:ZTS) by 10.5% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 3,511 shares of the company’s stock after selling 410 shares during the period. Sax Wealth Advisors LLC’s holdings in Zoetis were worth $548,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Lindbrook Capital LLC lifted its position in shares of Zoetis by 1.8% in the first quarter. Lindbrook Capital LLC now owns 3,715 shares of the company’s stock worth $612,000 after purchasing an additional 65 shares in the last quarter. Scott & Selber Inc. increased its holdings in Zoetis by 0.6% in the second quarter. Scott & Selber Inc. now owns 11,652 shares of the company’s stock worth $1,817,000 after buying an additional 67 shares during the last quarter. Secure Asset Management LLC increased its holdings in Zoetis by 2.9% in the second quarter. Secure Asset Management LLC now owns 2,448 shares of the company’s stock worth $382,000 after buying an additional 68 shares during the last quarter. Quotient Wealth Partners LLC increased its holdings in Zoetis by 2.3% in the first quarter. Quotient Wealth Partners LLC now owns 3,167 shares of the company’s stock worth $521,000 after buying an additional 72 shares during the last quarter. Finally, Menard Financial Group LLC increased its holdings in Zoetis by 3.8% in the first quarter. Menard Financial Group LLC now owns 2,032 shares of the company’s stock worth $305,000 after buying an additional 75 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently commented on ZTS shares. Leerink Partners downgraded Zoetis from an “outperform” rating to a “market perform” rating and dropped their price objective for the stock from $180.00 to $155.00 in a report on Thursday, July 17th. Leerink Partnrs downgraded Zoetis from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 17th. Weiss Ratings restated a “hold (c-)” rating on shares of Zoetis in a report on Wednesday. Argus restated a “buy” rating and issued a $190.00 price objective on shares of Zoetis in a report on Tuesday, September 9th. Finally, Stifel Nicolaus downgraded Zoetis from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $165.00 to $160.00 in a report on Wednesday, June 18th. Five research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $200.88.

Zoetis Trading Up 0.6%

Shares of ZTS stock opened at $143.61 on Thursday. Zoetis Inc. has a 12 month low of $139.34 and a 12 month high of $196.55. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. The business’s 50 day moving average is $149.41 and its two-hundred day moving average is $154.74. The company has a market cap of $63.65 billion, a PE ratio of 24.72, a price-to-earnings-growth ratio of 2.29 and a beta of 0.90.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, beating the consensus estimate of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The company had revenue of $2.46 billion for the quarter, compared to the consensus estimate of $2.41 billion. During the same quarter last year, the company posted $1.56 earnings per share. The company’s revenue for the quarter was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Equities analysts predict that Zoetis Inc. will post 6.07 EPS for the current year.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.